Cannabis has been used to treat gastrointestinal (GI) conditions that range from stomach and intestinal infections, inflammatory conditions, decreased motility, vomiting and abdominal pain.
The mechanistic basis of these treatments emerged after the discovery of certain constituents of full spectrum CBD oil -tetrahydrocannabinol. The receptors of tetrahydrocannabinol were identified as part of an endocannabinoid system, that consists of specific cannabinoid receptors, endogenous ligands and their biosynthetic and degradative enzymes. Anatomical, physiological and pharmacological studies have shown that the endocannabinoid system is widely distributed throughout the gut. It is involved in the regulation of food intake, nausea and vomiting, gastric secretion and gastroprotection, GI motility, ion transport, visceral sensation, intestinal inflammation and cell proliferation in the gut. Cannabinoid receptors and their high concentration and localization in the gut, contribute to healthy GI physiology when properly stimulated with tetrahydrocannabinols found in RESTRORE NUTRACEUTICALS™.